Topical Tranexamic Acid (TXA) in Joint Arthroplasty

Completed · Phase 4

Conditions studied: Osteoarthritis, Hip Arthropathy, Shoulder Arthropathy

In brief

The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in decreasing blood loss following both shoulder arthroplasty and primary total hip arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system within the body. The investigators hypothesize that topical application of TXA prior to closure reduces postoperative bleeding as measured by absolute changes in postoperative hemoglobin levels and surgical drain output. In addition, use of topically applied tranexamic acid may reduce the need for transfusions, the rates of hematomas, infections, and length of hospital stay.

Key facts

Study ID
NCT01937559
Run by
The Hawkins Foundation
People needed
188
Starts
2013-04-01
Expected to finish
2018-11-01
Last updated by the study team
2020-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.